Doximity (NYSE:DOCS) Director Sells $375,235.00 in Stock

Doximity, Inc. (NYSE:DOCS) Director Timothy Cabral sold 10,721 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total value of $375,235.00. Following the sale, the director owned 8,084 shares in the company, valued at approximately $282,940. The trade was a 57.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Doximity Price Performance

Shares of NYSE DOCS opened at $33.34 on Thursday. The firm’s 50-day moving average is $29.47 and its two-hundred day moving average is $25.40. The company has a market capitalization of $5.94 billion, a PE ratio of 46.31, a price-to-earnings-growth ratio of 33.78 and a beta of 1.29. Doximity, Inc. has a 12-month low of $17.15 and a 12-month high of $53.46.

Doximity (NYSE:DOCS) last announced its earnings results on Thursday, November 5th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.17. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The firm had revenue of $174.54 million for the quarter. During the same quarter last year, the company posted $0.45 EPS. Doximity’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts forecast that Doximity, Inc. will post 0.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wells Fargo & Company lowered Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price for the company. in a research note on Monday, August 10th. Piper Sandler restated an “overweight” rating and set a $47.00 price objective (up from $42.00) on shares of Doximity in a report on Friday, August 7th. Canaccord Genuity Group increased their target price on Doximity from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Raymond James Financial restated an “outperform” rating and set a $38.00 price target on shares of Doximity in a research note on Friday, October 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Doximity in a report on Friday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.59.

Hedge Funds Weigh In On Doximity

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Doximity during the 3rd quarter worth $45,000. Versant Capital Management Inc increased its position in Doximity by 1,176.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after acquiring an additional 1,683 shares during the period. Nisa Investment Advisors LLC boosted its position in Doximity by 59.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after acquiring an additional 695 shares during the period. Bessemer Group Inc. boosted its position in Doximity by 79.8% during the 3rd quarter. Bessemer Group Inc. now owns 1,910 shares of the company’s stock worth $54,000 after acquiring an additional 848 shares during the period. Finally, Fortitude Family Office LLC increased its holdings in shares of Doximity by 31,271.4% during the third quarter. Fortitude Family Office LLC now owns 2,196 shares of the company’s stock valued at $62,000 after purchasing an additional 2,189 shares during the period. 87.19% of the stock is owned by institutional investors.

Key Headlines Impacting Doximity

Investors following DOCS have been watching these headlines:

• Positive Sentiment: Doximity rolled out DoseCheck, a product highlighted in connection with near-zero drug-dosing errors. The launch could add value to its clinical workflow offerings, although the report provided no revenue outlook or adoption figures. Article: Doximity Rolls Out DoseCheck
• Neutral Sentiment: Barclays raised its price target from $27 to $30 but kept an “equal weight” rating. The higher target is a modest positive, though it remains below the $33.34 price cited in the supplied market data, signaling limited upside at that level. Article: Barclays price target
• Negative Sentiment: Several law firms reiterated a securities class action and the November 16 lead-plaintiff deadline. The suit alleges Doximity misled investors about Newsfeed engagement, competition, advertising formats and revenue performance; these claims are allegations, not proven findings. The litigation may sustain uncertainty and reputational risk. Article: Doximity class-action reminder

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.